Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.
Type:
Grant
Filed:
October 29, 2021
Date of Patent:
April 23, 2024
Assignee:
Immatics Biotechnologies GmbH
Inventors:
Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
Abstract: A 5-((2-isopropyl-5-methylphenoxy)methyl)-3-(naphthalen-2-yl)-1,2,4-oxadiazole compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
November 2, 2023
Date of Patent:
April 9, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: Provided herein, in some embodiments, are antibodies, antigen-binding antibody fragments, chimeric antigen receptors (CARs) and bispecific T cell engagers (BiTEs) that bind specifically to B7 homolog 6. Also provided herein are methods of using the same and cells comprising the same.
Type:
Grant
Filed:
May 12, 2021
Date of Patent:
April 9, 2024
Assignee:
TRUSTEES OF DARTMOUTH COLLEGE
Inventors:
Margaret Ackerman, Casey Hua, Charles Sentman
Abstract: Provided herein are compositions and methods for the treatment of cancer by inhibition of ?-catenin or a ?-catenin pathway. In particular, inhibitors of ?-catenin and/or the Wnt/?-catenin signaling pathway are employed prevent or reverse evasion of immune response or immunotherapy by cancers.
Abstract: Disclosed herein are methods of treating, reducing the incidence of, or preventing one or more activities in or of a cancer cell, methods of treating, reducing the incidence of, or preventing migration or metastasis of a cancer cell, methods of treating, reducing the incidence of, or preventing a cancer by reducing tumor associated macrophages (TAMs) or their migration, and methods of treating, reducing the incidence of, or preventing a cancer (including metastatic cancer), for example, with an inhibitor of Motile Sperm Domain containing Protein 2 (MOSPD2). Also disclosed are inhibitors of MOSPD2 (e.g., anti-MOSPD2 antibodies or antigen binding fragments thereof) and pharmaceutical compositions containing MOSPD2 inhibitors. Also disclosed are methods for the prediction, diagnosis, or prognosis of cancer, cancer metastasis, tumor progression, or tumor invasiveness in a subject.
Abstract: Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.
Type:
Grant
Filed:
October 2, 2018
Date of Patent:
April 2, 2024
Assignee:
VISTERRA, INC.
Inventors:
Bharat Chaganty, Boopathy Ramakrishnan, Hedy Adari-Hall, Karthik Viswanathan, James R. Myette, Zachary Shriver
Abstract: Given developing resistance of tumor cells to current chemotherapeutic and targeted therapeutic agents, novel cancer therapies with enhanced potency and specificity are substantially required. Applicant has provided herein extracellular nanoparticle vesicles that redirect immune effector cells towards cancer cells for killing. Relative to conventional immunotherapeutic antibodies with defined orientation and geometry for their distinct antigen-binding arms, antibodies displayed on spherical exosomes can promote formation of immunological synapses as well as enhanced efficacy to activate immune cells.
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
May 7, 2021
Date of Patent:
March 26, 2024
Assignee:
Immatics Biotechnologies GmbH
Inventors:
Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Colette Song
Abstract: The present disclosure provides compositions comprising chemerin and the methods of use thereof. The compositions of the disclosure are useful in the treatment of cancer.
Type:
Grant
Filed:
January 9, 2017
Date of Patent:
March 26, 2024
Assignee:
Washington University
Inventors:
Russell Pachynski, Holbrook Kohrt, Jason Yonehiro, Brian Zabel
Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
Type:
Grant
Filed:
April 5, 2018
Date of Patent:
March 26, 2024
Assignee:
LES LABORATOIRES SERVIER
Inventors:
Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
Abstract: The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.
Type:
Grant
Filed:
June 9, 2022
Date of Patent:
March 19, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of chimeric antigen receptors (CARs) and engineered immunoresponsive cells comprising the same. The engineered immunoresponsive cells comprising the novel CARs are antigen-directed and have extended persistence without compromising function.
Type:
Grant
Filed:
June 24, 2020
Date of Patent:
March 19, 2024
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER
Inventors:
Michel Sadelain, Judith Feucht, Mohamad Hamieh, Jie Sun, Jorge A. Mansilla-Soto
Abstract: A bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibody comprising a cytotoxic lymphocyte or macrophage targeting domain and an autoantibody. Methods for producing bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibody comprising a cytotoxic lymphocyte or macrophage targeting domain and an autoantibody. Methods for treating a subject in need thereof comprising administering to the subject an isolated bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibody.
Type:
Grant
Filed:
March 17, 2020
Date of Patent:
February 27, 2024
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
Andrew Tsourkas, James Z. Hui, Burcin Altun, Fabiana Zappala
Abstract: Disclosed are methods for treating a cancer and/or enhancing immune responses to infiltration of tumors comprising administering to a subject a fucose. Also disclosed herein are methods of detecting the presence of a sugar-modified protein (i.e., a glycosylated protein).
Type:
Grant
Filed:
October 15, 2018
Date of Patent:
February 27, 2024
Assignee:
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Abstract: Provided herein are bedside systems and methods for performing customized cell-based therapies and treatments in a patient-connected, closed-loop continuous-flow manner, including cellular modifications and treatments, e.g., to produce chimeric antigen receptor-T (CAR-T) cells among other cellular modifications and treatments.
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets an immune checkpoint molecule. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
February 13, 2024
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals
Inventors:
David B. Weiner, Kar Muthumani, Niranjan Sardesai
Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.
Type:
Grant
Filed:
February 10, 2021
Date of Patent:
February 13, 2024
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
Abstract: The present disclosure relates to antibodies that specifically bind human IL-4R?, compositions comprising such IL-4R? antibodies, and methods of using such IL-4R? antibodies.
Type:
Grant
Filed:
August 5, 2022
Date of Patent:
February 6, 2024
Assignee:
ELI LILLY AND COMPANY
Inventors:
Shane Krummen Atwell, Yiqing Feng, Maya Rachel Karta, Donmienne Leung, Songqing Na, Diana Isabel Ruiz, David John Stokell, Laura Anne Pelletier
Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
Type:
Grant
Filed:
September 29, 2020
Date of Patent:
February 6, 2024
Assignee:
FAMEWAVE LTD.
Inventors:
Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
Abstract: Multi-specific binding proteins that bind HER2, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
Type:
Grant
Filed:
February 20, 2018
Date of Patent:
January 30, 2024
Assignee:
Dragonfly Therapeutics, Inc.
Inventors:
Gregory P. Chang, Ann F. Cheung, William Haney, Bradley M. Lunde, Bianka Prinz